Disease modification in rheumatoid arthritis with special reference to cyclosporin A.
Disease modifying antirheumatic drugs improve clinical markers of synovial inflammation as well as acute phase reactants and functional status in patients with rheumatoid arthritis. Some of the disease modifying antirheumatic drugs probably also retard radiographic progression. Data from prospective observational studies and epidemiological studies indicate a modest and temporary effect. New treatment modalities are needed, including both new strategies and new drugs. Cyclosporin A improves clinical markers of synovial inflammation and is useful for individual patients with rheumatoid arthritis. However, further studies are required to investigate the long term efficacy and tolerance of cyclosporin in rheumatoid arthritis.